Table 2 Association between comorbidity and the development of atrial fibrillation (binary conditional logistic regression analysis, n = 8452)

Cardiovascular medication^a

 Diuretic

1.7 (1.5–1.9)

<0.001

1.1 (0.94–1.3)

0.24

 β blocker

2.0 (1.8–2.2)

<0.001

1.6 (1.4–1.8)

<0.001

 Calcium channel blocker

1.8 (1.5–2.0)

<0.001

1.3 (1.1–1.5)

0.003

 ACE-inhibitor

1.8 (1.6–2.1)

<0.001

1.3 (1.1–1.5)

0.008

 ARB

1.5 (1.2–1.8)

<0.001

1.1 (0.85–1.3)

0.63

Comorbidity^a

 Charlson Comorbidity Index (per point increase)

1.12 (1.08–1.16)

<0.001

1.09 (1.05–1.14)^b

<0.001

  Myocardial infarction

1.8 (1.5–2.1)

<0.001

1.3 (1.0–1.5)

0.021

  Heart failure

3.3 (2.7–4.0)

<0.001

2.5 (2.0–3.1)

<0.001

  Peripheral vascular disease

1.4 (1.1–1.7)

0.001

1.0 (0.82–1.3)

0.89

  Cerebrovascular event

1.6 (1.3–1.8)

<0.001

1.3 (1.1–1.6)

0.003

  Dementia

0.89 (0.66–1.2)

0.43

0.86 (0.62–1.2)

0.37

  Chronic pulmonary disease

1.0 (0.71–1.4)

0.99

0.94 (0.66–1.3)

0.72

  History of peptic ulcers

1.2 (0.96–1.4)

0.12

1.0 (0.82–1.3)

0.92

  Liver disease

1.1 (0.83–1.5)

0.47

0.99 (0.72–1.4)

0.96

  Diabetes

1.4 (1.2–1.6)

<0.001

1.1 (0.89–1.2)

0.58

  Hemiplegia

1.5 (0.98–2.3)

0.058

1.1 (0.71–1.8)

0.61

  Renal disease

1.5 (1.3–1.8)

<0.001

1.4 (1.1–1.7)

0.001

  History of tumours

0.92 (0.79–1.1)

0.31

0.86 (0.73–1.02)

0.086

  Leukaemia

0.77 (0.29–2.0)

0.59

0.65 (0.22–1.9)

0.44

  Lymphoma

0.75 (0.33–1.7)

0.49

0.85 (0.36–2.0)

0.72

 Hypertension

1.5 (1.4–1.7)

<0.001

1.1 (0.97–1.3)

0.15

 Valve disease

3.1 (2.5–3.8)

<0.001

2.5 (2.0–3.1)

<0.001